


Z-VAD(OMe)-FMK

| | | |
|----------------------|--|---------------|
| Cat. No.: | HY-16658 | |
| CAS No.: | 187389-52-2 | |
| Molecular Formula: | C ₂₂ H ₃₀ FN ₃ O ₇ | |
| Molecular Weight: | 467.49 | |
| Sequence: | Z-Val-Ala-Asp(OMe)-FMK | |
| Sequence Shortening: | ZVA-D(OMe)-FMK | |
| Target: | Caspase | |
| Pathway: | Apoptosis | |
| Storage: | Powder | -20°C 3 years |
| | In solvent | -80°C 2 years |
| | | -20°C 1 year |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (213.91 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent | | Mass | | |
|---------------------------|---------------|--|-----------|------------|------------|
| | Concentration | | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 2.1391 mL | 10.6954 mL | 21.3908 mL |
| | 5 mM | | 0.4278 mL | 2.1391 mL | 4.2782 mL |
| | 10 mM | | 0.2139 mL | 1.0695 mL | 2.1391 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution
- Add each solvent one by one: 1% DMSO >> 99% saline
Solubility: ≥ 0.52 mg/mL (1.11 mM); Clear solution

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor ^[1] . Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1 ^[2] . |
| IC₅₀ & Target | Caspase |
| In Vitro | Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a broad-spectrum caspase inhibitor, has been shown to inhibit the intracellular activation of caspase-like proteases. The injection of Z-VAD(OMe)-FMK suppresses the caspase-3 activity in lung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells ^[1] . Z-VAD(OMe)-FMK effectively inhibits UCHL1's reaction with hemagglutinin-tagged ubiquitin vinylmethyl ester (HA-UbVME) at the concentration of 100 μM ^[2] . Z-VAD(OMe)-FMK is administered intraperitoneally at 1 hour before and 6 hours after SAH. Expression of caspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD(OMe)-FMK suppresses TUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBB permeability, relieves vasospasm, abolishes brain edema, and improves neurological outcome ^[3] . Z-VAD(OMe)-FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMN deficiency ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | The survival rate of mice is prolonged significantly by the injection of Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK). All mice succumbed to LPS within 30 hours. By contrast, the mice treated with Z-VAD(OMe)-FMK survive significantly longer and 27% of the mice survived more than 7 days ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

PROTOCOL

| | |
|--|--|
| Cell Assay ^[4] | <p>PCR products containing coding sequences for the dSMN (forward primer: 5'-TAA TAC GAC TCA CTA TAG GG AAG ACG TAC GAC GAG TCG-3'; and reverse primer: 5'-TAA TAC GAC TCA CTA TAG GG GTG GTG CTG GCT TCT TTC-3'; product length, 601bps; bold and italics letters represent T7 promoter sequences) and control <i>Drosophila</i> Presenilin (dPsn) gene (forward primer: 5'-TAA TAC GAC TCA CTA TAG GG TG GCT GCT GTC AAT CTC-3'; and reverse primer: 5'-TAA TAC GAC TCA CTA TAG GG CGA TAG CAA CGC TTC TTG-3'; product length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) are generated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. The dsRNA products are ethanol precipitated and annealed by incubation at 65°C for 30 min and then slowly allowed to cool at room temperature. The annealed dsRNA products are analyzed on a 1% agarose gel to ensure the majority of dsRNA existed as a single band. The dsRNA (2 μg) and/or plasmid DNAs (2 μg) are introduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 μM of Z-VAD(OMe)-FMK in the culture medium^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |
| Animal Administration ^{[1][3]} | <p>Mice^[1]</p> <p>Mice used in this study are 5- to 6-week-old (20 to 22 g) ICR males. Mice are injected with 30 mg/kg LPS from <i>E. coli</i> serotype O111:B4 through the tail vein. A single intravenous injection of Z-VAD(OMe)-FMK (0.25 mg) is made 15 minutes before LPS injection, followed by three intravenous injections of Z-VAD(OMe)-FMK (0.1 mg each) per hour. Control mice are injected with the same volume of 1% DMSO in sterile saline.</p> <p>Rats^[3]</p> <p>Male Sprague-Dawley rats weighing 300 to 350 g are anesthetized with α-chloralose (40 mg/kg IP) and urethane (400 mg/kg IP). Animals are intubated, and respiration is maintained with a small animal respirator. Rectal temperature is maintained at 37±0.5°C with a heating pad. The left external carotid artery is isolated and a 4.0 monofilament nylon suture is inserted through the internal carotid artery to perforate the middle cerebral artery. SAH is confirmed at autopsy in each rat. Sham-operated rats underwent the same procedures except that the suture is withdrawn after resistance is felt. Z-VAD(OMe)-FMK (50 μM per 0.3 mL) is injected intraperitoneally at 1 hour before and 6 hours after SAH induction. In vehicle group, rats underwent SAH induction and are treated with the same volume of vehicle (DMSO diluted in physiological buffer solution). No treatment is applied in sham-operated animals.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

CUSTOMER VALIDATION

- Nature. 2020 Apr;580(7803):386-390.
- Cell. 2020 Mar 5;180(5):941-955.e20.
- Cell. 2018 Sep 6;174(6):1477-1491.e19.
- Cell Res. 2023 Sep 19.
- Cell Res. 2018 Dec;28(12):1171-1185.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. *Am J Pathol.* 2000 Aug;157(2):597-603.
- [2]. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. *Stroke.* 2004 Oct;35(10):2412-7.
- [3]. Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. *J Biol Chem.* 2003 Aug 15;278(33):30993-9.
- [4]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). *Bioorg Med Chem Lett.* 2012 Jun 15;22(12):3900-4.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA